GRANIX (TBO-FILGRASTIM) INJECTION Trademark of TEVA Pharmaceutical Industries Limited Serial Number: 86040042 :: Trademarkia Trademarks
Teva - Contract Pharma
TEVA PHARMACEUTICALS USA, INC: Teva Announces Updated Indication and Vial Presentation for GRANIX® (tbo-filgrastim) Injection in United States | American Pharmacy News
Market Share by Filgrastim Brand (As a Percentage of Sales Before Rebates) | Download Scientific Diagram
Teva Pharmaceuticals - pdf download
GRANIX - TEVA Pharmaceutical Industries Limited Trademark Registration
Rx Item-Granix 300MCG 10X1 ML Single Dose Vial -Keep Refrige
Print — Cathy McCartney
Biosimilar… but different: FDA tweaking nonproprietary name guidance - BioProcess InternationalBioProcess International
Granix Indication Expanded to Include Pediatric Patients - MPR
ACTAVIS: Teva Announces Updated Indication and Vial Presentation for GRANIX® (tbo-filgrastim) Injection in United States | American Pharmacy News
These highlights do not include all the information needed to use GRANIX safely and effectively. See full prescribing information for GRANIX.GRANIX® (tbo-filgrastim) injection, for subcutaneous use Initial U.S. Approval: 2012
Teva bolsters its biosimilar business through $160m Celltrion deal
NDC 63459-910 Granix Tbo-filgrastim
63459091236 - Henry Schein Medical
15_03.jpg
Granix® Hematopoietic Agent TBO-Filgrastim, Preservative Free 480 mcg / 0.8 mL Subcutaneous Injection Prefilled Syringe 5 Syringes
A Look at Teva's Dominance in the Biosimilar Space
Granix
BUY tbo-filgrastim (GRANIX) 300 ug/.5mL Cephalon, Inc.
NDC 63459-910 Granix Tbo-filgrastim
GRANIX - TEVA Pharmaceutical Industries Limited Trademark Registration
Updated Indication For Teva's Granix Injection Approved In U.S. - Drug Discovery and Development
